## DHR: Danaher Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.9% below STRENGTH zone (4.0-10.0%); PEG 1.99 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($216.43)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 3, Bearish: 2)

**1. Danaher (DHR) Valuation Check After Analyst Upgrade and 2026 Earnings Recovery Narrative**
- Source: Simply Wall Street | 20251204T163645 | Somewhat-Bullish | Relevance: 100%
- Morgan Stanley's upgrade has put Danaher (DHR) on watchlists, fueled by optimism for a 2026 recovery through core revenue growth and earnings leverage. While currently appearing undervalued at $228.46 against a narrative fair value of $254.20, its P/E ratio of 46.1x suggests a tougher valuation story compared to its industry. The long-term narrative focuses on precision medicine and AI-assisted diagnostics driving EBITDA expansion, though risks like China policy shifts and biotech funding weakness could impact recovery.

**2. Danaher Corporation (DHR): A Bull Case Theory**
- Source: Finviz | 20251204T135900 | Bullish | Relevance: 100%
- This article summarizes a bullish thesis on Danaher Corporation (DHR), highlighting its consistent long-term wealth creation, strong financial performance, and quality metrics. Despite recent consolidation, Danaher shows resilience with margin expansion, strategic acquisitions, and share buybacks, positioning it as a resilient compounder with both defensive qualities and upside potential. The company benefits from secular trends and disciplined capital allocation.

**3. Jim Cramer Says "Danaher's Been Acting Much Better"**
- Source: Finviz | 20251204T000500 | Bullish | Relevance: 100%
- Jim Cramer discussed Danaher Corporation (NYSE: DHR), noting its recent improved performance despite past frustrations for his Charitable Trust. The company saw a strong quarter driven by its bioprocessing division, with a revenue beat and solid organic growth, leading to a significant stock rally. Cramer still likes DHR but is considering trimming the position if the stock jumps another 10 points.

**4. Marshall Wace LLP Cuts Holdings in Danaher Corporation $DHR**
- Source: MarketBeat | 20251205T125051 | Somewhat-Bearish | Relevance: 100%
- Marshall Wace LLP significantly reduced its stake in Danaher Corporation (NYSE:DHR) by 76.6% in the second quarter, selling over 2.7 million shares but still holding 0.12% of the company worth $166.9 million. This move comes alongside notable insider selling of Danaher stock within the last 90 days. Despite the institutional and insider selling, Danaher reported an EPS beat with 4.4% revenue growth and maintains an average analyst rating of "Moderate Buy."

**5. Bronstein, Gewirtz & Grossman, LLC Is Investigating Danaher Corporation (DHR) And Encourages Investors to Connect**
- Source: WRIC ABC 8News | 20251204T160929 | Somewhat-Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Danaher Corporation (NYSE:DHR) who bought securities prior to April 21, 2022, and still hold them. The investigation focuses on whether Danaher and its officers engaged in corporate wrongdoing. Investors are encouraged to contact the firm for more information.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $270 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.20M) |
| Sells | 10 ($75.99M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 8.6% (+0.2%)
- Blackrock Inc.: 7.4% (+0.1%)
- JPMORGAN CHASE & CO: 5.3% (+404.7%)
- State Street Corpora: 3.9% (-0.3%)
- Capital Internationa: 2.4% (+1.9%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-1.6% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $76M sold (10 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.99 elevated, pricing in significant growth expectations. Forward P/E 26.9x stretched relative to 9% growth. Balance sheet: $1.4B free cash flow. Insider selling cluster ($76.0M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $164.9B |
| Beta | 0.92 |
| 52W Range | $171.00 - $258.23 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.99 |
| Forward P/E | 26.9 |
| Current P/E | 29.3 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.7% to -0.9% (-1.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.9pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. OFD pattern: -MLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.92% (CS: 46) | Neutral |
| RSI_14 | 58.1 | Neutral |
| MACD Histogram | -0.27 | Bearish |
| vs SMA20 | 1.014x | Above |
| vs SMA50 | 1.051x | Above |
| vs SMA200 | 1.114x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $226.25
- **Stop Loss:** $216.43 (4.3% risk)
- **Target:** $236.07 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 50
- **Position Value:** $11,312.50
- **Portfolio %:** 11.31%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-01-28 (Est: $2.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.72 | $1.89 | +9.8% |
| 2025Q2 | $1.64 | $1.80 | +9.5% |
| 2025Q1 | $1.64 | $1.88 | +14.4% |
| 2024Q4 | $2.16 | $2.14 | -1.1% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*